### 1 **Title: Community carriage of ESBL-producing** *Escherichia coli* **and** *Klebsiella*

### 2 *pneumoniae***: A cross-sectional study of risk factors and comparative genomics of**

### 3 **carriage and clinical isolates**



- *<sup>a</sup>* 12 *Department of Microbiology and Infection Control, University Hospital of North Norway,*  13 *Tromsø, Norway*
- *<sup>b</sup>* 14 *Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of*
- 15 *Norway, Tromsø, Norway*
- *<sup>c</sup>* 16 *Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway,*
- 17 *Tromsø, Norway*
- *<sup>d</sup>* 18 *Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of*
- 19 *Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway*
- *<sup>e</sup>* 20 *Department of Biostatistics, University of Oslo, Oslo, Norway*
- *<sup>f</sup>* 21 *Department of Medical Microbiology, Stavanger University Hospital, Stavanger, Norway*
- *<sup>g</sup>* 22 *Collaborators forming the Norwegian E. coli ESBL Study Group are listed in the*
- 23 *Acknowledgement.*



- *Nordbyhagen, Norway*
- *<sup>i</sup> Division of Medicine and Laboratory Sciences, Institute of Clinical Medicine, University of*
- *Oslo, Oslo, Norway*
- 28  $*$  equal contribution
- 29 \*Corresponding author: Niclas Raffelsberger, Correspondence address: Department of
- 30 Microbiology and Infection Control, University Hospital of North Norway, N-9038 Tromsø,



- 
- 
- 
- 
- 

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

## 45 **Abstract**

46 The global prevalence of infections caused by ESBL-producing Enterobacterales (ESBL-E) is 47 increasing and for *Escherichia coli* observations indicate that this is partly driven by 48 community-onset cases. The ESBL-E population structure in the community is scarcely 49 described and data on risk factors for carriage are conflicting. Here, we report the prevalence 50 and population structure of fecal ESBL-producing *E*. *coli* and *Klebsiella pneumoniae* (ESBL-51 Ec/Kp) in a general adult population, examine risk factors, and compare carriage isolates with 52 contemporary clinical isolates.

53 Fecal samples obtained from 4999 participants (54% women) ≥40 years in the seventh survey 54 of the population-based Tromsø Study, Norway (2015-2016) were screened for ESBL-Ec/Kp. 55 In addition, we included 118 ESBL-Ec clinical isolates from the Norwegian surveillance 56 program in 2014. All isolates were whole-genome sequenced. Risk factors associated with 57 carriage were analyzed using multivariable logistic regression.

58 ESBL-Ec gastrointestinal carriage prevalence was 3.3% (95% CI 2.8-3.9%, no sex difference) 59 and 0.08% (0.02-0.20%) for ESBL-Kp. For ESBL-Ec, travel to Asia was the only 60 independent risk factor (AOR 3.47, 95% CI 2.18-5.51). *E. coli* ST131 was most prevalent in 61 both collections. However, the ST131 proportion was significantly lower in carriage (24%) 62 vs. clinical isolates (58%, p<0.001). Carriage isolates were genetically more diverse with a 63 higher proportion of phylogroup A  $(26\% \text{ vs. } 5\%, \text{ p} < 0.001)$ , indicating that ESBL gene 64 acquisition occurs in a variety of *E. coli* lineages colonizing the gut. STs commonly related to 65 extra-intestinal infections were more frequent in clinical isolates also carrying a higher 66 prevalence of antimicrobial resistance, which could indicate clone associated pathogenicity.

<sup>67</sup>**Keywords:** *Escherichia coli*, *Klebsiella pneumoniae*, Extended-spectrum β-lactamase, 68 antimicrobial resistance, carriage, risk factors, general population, bacterial genomics

## 69 **Importance**

70 ESBL-producing *E. coli* (ESBL-Ec) and *K. pneumoniae* (ESBL-Kp) are major pathogens in 71 the global burden of antimicrobial resistance. However, there is a gap in knowledge 72 concerning the bacterial population structure of human ESBL-Ec/Kp carriage isolates in the 73 community. We have examined ESBL-Ec/Kp isolates from a population-based study and 74 compared these to contemporary clinical isolates. The large genetic diversity of carriage 75 isolates indicates frequent ESBL gene acquisition, while those causing invasive infections are 76 more clone dependent and associated with a higher prevalence of antibiotic resistance. The 77 knowledge of factors associated with ESBL carriage helps to identify patients at risk to 78 combat the spread of resistant bacteria within the healthcare system. Particularly, previous 79 travel to Asia stands out as a major risk factor for carriage and should be considered in 80 selecting empirical antibiotic treatment in critically ill patients.

81

## 82 **Introduction**

83 Extended spectrum β-lactamase (ESBL) producing *Escherichia coli* (ESBL-Ec) and 84 *Klebsiella pneumoniae* (ESBL-Kp) are major contributors to the global burden of disease due 85 to antibiotic resistant bacteria.<sup>1</sup> The prevalence of infections caused by ESBL-Ec or ESBL-Kp 86 is increasing, even in countries with low antibiotic use and availability on prescription only, 87 like Norway.<sup>2</sup> The mortality of invasive infections with ESBL-producing Enterobacterales 88 (ESBL-E) ranges from 10-35%, depending on bacterial species, host factors, severity of 89 disease and initial antibiotic therapy.<sup>3,4</sup> Consequently, ESBL-Ec/Kp are high-priority 90 pathogens when developing new drugs to combat the threat from antibiotic resistant bacteria.<sup>5</sup>

91 ESBL-Ec/Kp colonization precedes invasive infections<sup>6-8</sup> and recent reviews report an 92 increasing global prevalence of human ESBL-E carriage in the community, with an 8-fold rise 93 over the past two decades.<sup>9,10</sup> The highest prevalence is detected in Asian and African regions (20-70%), the lowest in Europe and the Americas  $\left(\langle 10\% \right)^{9,10}$  A study from the USA shows 95 that the increased incidence of ESBL-Ec infections was driven by an increase in community-96 onset cases<sup>11</sup>, and human-to-human transmission was the attributable source to 60% of 97 community-acquired gastrointestinal ESBL-Ec carriage in the Netherlands  $^{12}$ .

98 Several risk factors for ESBL-E gastrointestinal carriage have been described. However, these 99 have, with a few exceptions<sup>13,14</sup>, mainly been investigated in small and/or selected study 100 populations, such as international travelers<sup>15</sup>, patients with gastroenteritis<sup>16</sup>, patients recruited 101 by general practitioners<sup>17</sup>, persons with recent healthcare contact<sup>18</sup>, pregnant women<sup>19</sup>, 102 children<sup>20</sup> or persons living in a livestock-dense area<sup>21</sup>. Many studies have identified 103 international travel as a risk factor for ESBL acquisition, whilst the significance of sex, age, 104 antibiotic or proton pump inhibitor use, hospitalization and diet are conflicting.<sup>13-15,17,18,22-24</sup>

105 We have comprehensive knowledge of the prevalence and population structure of clinical 106 ESBL-E isolates showing a dominance of CTX-M-group ESBL enzymes and the association 107 with specific extraintestinal pathogenic *E. coli* (ExPEC) and multidrug-resistant *K.*  108 *pneumoniae* high-risk clones.<sup>25-28</sup> Large-scale genomic studies have identified specific 109 subclades of *E. coli* sequence type (ST) 131 and *K. pneumoniae* ST307 as major contributors 110 to the increasing prevalence of ESBL infections.<sup>25,27,29,30</sup> Community-based studies from the 111 Netherlands and Sweden also observed a predominance of ST131, but a high genetic diversity 112 within the ESBL-Ec population.<sup>13,14</sup>

113 Improved knowledge of risk factors for ESBL-E carriage and their population structure in the 114 general human population may provide information for risk stratification and targeted 115 infection control measures. It is important to consider ESBL-E carriage in critically ill septic 116 patients with respect to the choice of empirical antibiotic treatment. The aims of this study 117 were to examine the prevalence of, and risk factors associated with, ESBL-Ec/Kp 118 gastrointestinal carriage in a general adult population in Norway, and to compare the ESBL-119 Ec population structure with a national collection of clinical isolates.

### 120 **Results**

121 We detected gastrointestinal carriage of putative ESBL-Ec/Kp in 188 of 4,999 randomly 122 selected participants who provided fecal samples in the seventh survey of the population-123 based Tromsø study (Tromsø $7^{31}$  (Suppl. Table 1, Figure 1). Overall, 87% of participants 124 receiving a sampling kit returned a fecal sample. In total, 180 Ec and nine Kp putative ESBL-125 positive isolates were isolated from the 188 ESBL screening-positive fecal samples. Both 126 ESBL-Ec and -Kp were detected in one sample.



128 **Figure 1.** Flowchart and results of fecal sample screening for gastrointestinal carriage of 129 ESBL-producing *E. coli* and *K. pneumoniae* in 4,999 participants in Tromsø7, 2015-2016.

130 Pheno- and genotypic analyses showed that 14 putative ESBL-Ec isolates were either pheno-

131 and/or genotypically ESBL-negative. Of these, one isolate harbored plasmid-mediated AmpC

132 (*bla*<sub>CMY-2</sub>). After exclusion of the ESBL-negative isolates, prevalence of ESBL-Ec

133 gastrointestinal carriage was 3.3% (95% confidence interval (CI) 2.8-3.9%, 166 of 4,999

134 participants); 3.1% (2.5-3.9%) in women and 3.5% (2.8-4.4%) in men.

135 Among the nine screening ESBL-positive Kp isolates, one harbored *bla*<sub>CMY-2</sub> and four did not

- 136 express an ESBL phenotype. Consequently, four samples were considered positive for ESBL-
- 137 producing Kp, corresponding to a prevalence of 0.08% (0.02-0.20%), all among male
- 138 participants.

#### 139 *Factors associated with gastrointestinal carriage of ESBL-E. coli*

140 We analyzed data from 4,996 participants, excluding those three who were positive for 141 ESBL-Kp only (Suppl. Table 1). Median age was 65 years (interquartile range 58-70 years, 142 no sex difference). In multivariable logistic regression analyses adjusted for all explanatory 143 variables, only travel to Asia the past 12 months was associated with ESBL-Ec 144 gastrointestinal carriage with an adjusted odds ratio (AOR) of 3.47 (2.18-5.51) (Table 1). 145 Among participants reporting hospitalization in the past year, or recent use of antibiotics or 146 acid suppressive medication, we observed a non-significant increase in prevalence of ESBL-147 Ec.

148 **Table 1.** ESBL-producing *E. coli* gastrointestinal carriage and associated factors among 4,996 149 participants in Tromsø7.

Characteristics	$\%$	$\mathbf n$	N	<b>AOR</b>	95% CI	p-value
	(ESBL-	(ESBL-				
	E. coli	$E.$ coli)				
Age (years)						0.236
$40 - 49$	3.6	22	605	1.00		
50-59	4.1	33	814	1.15	$0.66 - 2.01$	
60-69	3.2	68	2,127	0.81	$0.49 - 1.33$	
70-84	3.0	43	1,450	0.73	$0.42 - 1.26$	
Hospitalization past 12 months						0.128
N <sub>0</sub>	3.3	142	4,341	1.00		
Yes	4.0	24	593	1.43	$0.90 - 2.27$	
Antibiotic use past 14 days <sup>a</sup>						0.258
N <sub>0</sub>	3.3	158	4,831	1.00		
Yes	5.2	8	153	1.58	0.72-3.47	
Acid suppressive medication past 4 weeks						0.951
Not used	3.3	123	3,760	1.00		
$\leq$ weekly	3.2	13	402	1.02	$0.57 - 1.83$	
Every week, but not daily	3.5	9	260	1.10	$0.55 - 2.20$	
Daily	3.7	11	297	1.20	$0.63 - 2.26$	
Travel abroad past 12 months <sup>b</sup>						< 0.001
N <sub>0</sub>	2.5	53	2,145	1.00		
Other regions (excl. Asia)	3.2	70	2,212	1.36	0.93-1.98	
Asia exclusively or $Asia + other$ regions	8.2	38	461	3.47	2.18-5.51	
Traveler's diarrhea past 12 months <sup>c</sup>						0.972
N <sub>0</sub>	3.3	156	4,721	1.00		
Yes	4.8	8	166	1.01	$0.48 - 2.16$	

ESBL, extended spectrum  $\beta$ -lactamase; N, denominator; AOR, adjusted odds ratio; CI, confidence interval; AOR adjusted for age, hospitalization past 12 months, antibiotic use past 14 days, acid suppressive medication past 152 12 months and traveler`s diarrhea past 12 months.

The multivariable model includes 4,488 participants with complete information on all variables.

<sup>a</sup> Have you taken any antibiotics (tablets or oral suspensions, nasal ointments, eye drops or eye ointment) during the past 14  $\frac{days}{b}$ 

Traveled outside the Nordic countries  $>1$  week duration in the past 12 months.

<sup>c</sup> For each travel abroad the past 12 months, the participants were asked if they had experienced diarrhea in connection with the travel.

150<br>151<br>152<br>153<br>154<br>155<br>155<br>157<br>158<br>159 160

161 Both in the literature and in our previous study<sup>32</sup>, we identified several factors associated with 162 Kp gastrointestinal carriage, overlapping with those associated with ESBL-Ec 163 carriage.<sup>15,22,33,34</sup> Thus, in 2,972 participants (of the total 4,996 participants in this current 164 study) previously screened for Kp, we performed a multivariable logistic regression analysis 165 including Kp carriage as an additional explanatory variable (Suppl. Table 2). Prevalence of 166 ESBL-Ec gastrointestinal carriage was 2.7% among participants without Kp carriage and 167 4.8% (p=0.016) among those with Kp carriage. In the full model, AOR was 1.66 (0.99-2.79, 168 p=0.055), indicating a possible association between Kp and ESBL-Ec carriage.

### 169 *Comparative analysis of ESBL-E. coli carriage and clinical isolates*

170 To explore the population structure and genomic characteristics of ESBL-Ec in community

171 carriage we whole-genome sequenced (WGS) all 166 isolates. Furthermore, we sequenced a

172 contemporary national collection of 118 clinical ESBL-Ec isolates (NORM 2014) for

173 comparative analysis (Figure 2, Suppl. Table 3).



- $\frac{174}{175}$ Figure 2. Maximum-likelihood phylogenetic tree based on core genome alignment of the 176 genomes of ESBL-*E. coli* carriage isolates from Tromsø7 (labeled grey, n=166) and clinical 177 isolates from NORM 2014 (blood isolates labeled with red and urine isolates with yellow, 178 n=118). The innermost ring illustrates phylogroups, followed by a ring with sequence types 179 (STs), a ring with ST131 subclades, and a ring with *fimH* types (ND, not detected). The 180 heatmap shows presence (blue color) or absence (white) of ESBL gene variants.
- 181

182 At the phylogroup level, 52.4% of the ESBL-Ec carriage isolates belonged to either 183 phylogroup A (26.5%) or D (25.9%), and 33.7% belonged to phylogroup B2 (Figure 2 and 184 Figure 3, Suppl. Table 3). This contrasts with the clinical isolates where 64.4% (p<0.001) of 185 the isolates belonged to phylogroup B2 and only 20.4% (p<0.001) belonged to phylogroup A

186 (5.1%) and D (15.3%) combined.



188 **Figure 3.** Phylogroup (labeled on the top) and sequence type (ST) distribution of ESBL-*E.* 



190 Carriage isolates had higher ST diversity (Figure 2 and 3, Suppl. Table 3) with Simpson's 191 diversity index 92.4% compared to clinical isolates (65.9%, p<0.001). We identified 58 192 different STs among the carriage isolates while the clinical isolates included 27 STs (Figure 2 193 and 3, Suppl. Table 3). ST131 (phylogroup B2) was the dominant ST in both collections, 194 however, more prevalent among clinical isolates (57.6%, n=68) than carriage isolates (24.1%, 195 n=40, p<0.001). Comparison of prevalence of ESBL-producing ST131 colonization vs. 196 infection in our study results in a crude odds ratio (OR) for infection of 4.3 (2.57-7.13, 197 p<0.001).

198 Within ST131, the multidrug resistant subclades C1 (alternatively referred to as *H*30-R) and 199 C2 (*H*30-Rx) accounted for 67.5% in carriage and 73.5% clinical isolates (Figure 2, Suppl. 200 Figure 1, Suppl. Table 3). The subclade C1 (47.5%, n=19) was the most prevalent among 201 carriage isolates and C2 (42.6%, n=29) among clinical isolates. The difference in the 202 proportion of C2 between clinical and carriage isolates was statistically significant (20.0%, 203 n=8, p=0.017). For the overall ESBL-Ec population, crude OR for infection among C2 was 204 6.44 (2.82-14.68, p<0.001) (Suppl. Table 4).

205 Although non-significant, a higher proportion of subclades A, B and B0, less associated with 206 antibiotic resistance, was observed among ST131 carriage isolates (32.5%) than clinical 207 isolates (26.5%, p=0.508) (Suppl. Figure 1). However, with regard to the overall ESBL-Ec 208 population, subclade A was associated with infection (carriage 6.0% vs. clinical 13.6%, OR 209 2.45, 1.07-5.60, p=0.034) (Suppl. Table 4).

210 The most prevalent STs in carriage isolates following ST131 were ST10 (7.2%, n=12, 211 phylogroup A), ST69 (7.2%, n=12) and ST38 (6.6%, n=11, both phylogroup D) compared to 212 ST405 (7.6%, n=9), ST38 (5.9%, n=7, both phylogroup D), and ST648 (5.1%, n=6, 213 phylogroup F) in clinical isolates (Figure 2 and 3, Suppl. Table 3). We did not identify the 214 common ExPEC lineage ST73<sup>25,29</sup> among the carriage isolates but found one ST95<sup>25,29</sup> (0.6%)

215 and five isolates of the emerging ST1193<sup>35,36</sup> (3.0%).

216 Using a single nucleotide polymorphism (SNP) cut-off of  $\leq 17^{37}$ , we detected two putative

217 clusters (Suppl. Table 5) among five of 284 isolates. All five were carriage isolates. One

- 218 ST357 cluster (6-9 SNP differences) consisted of three isolates and the other cluster of two
- 219 ST131 isolates (4 SNP difference). We detected no clusters among the clinical isolates.

# 220 *Antimicrobial resistance and plasmid replicon content*

- 221 CTX-M enzymes accounted for at least 97.0% of the ESBL phenotypes in both collections
- 222 (Figure 2 and Figure 4, Suppl. Table 3). The most prevalent ESBL genes among both carriage
- 223 and clinical isolates were  $bla_{\text{CTX-M-15}}$  (40.4%, n=67 vs. 61.0%, n=72, p=0.001),  $bla_{\text{CTX-M-14}}$
- 224 (20.5%, n=34 vs. 14.4%, n=17, p=0.188), and *bla*c<sub>TX-M-27</sub> (19.9%, n=33 vs. 15.3%, n=18,
- 225 p=0.321). One clinical isolate of ST38 harbored both  $bla_{\text{CTX-M-15}}$  and  $bla_{\text{CTX-M-14}}$ .  $Bla_{\text{CTX-M-3}}$ ,
- 226 *bla*CTX-M-8, *bla*CTX-M-32 and *bla*CTX-M-101 were exclusively detected in carriage isolates, whereas
- 227 *bla*<sub>CTX-M-24</sub> and *bla*<sub>CTX-M-104</sub> were present only in clinical isolates. The remaining ESBL
- 228 producers contained  $bla_{\text{SHV-12}}$  in 3.0% of the carriage and 1.7% of the clinical isolates.  $Bla_{\text{TEM}}$
- 229 ESBL genes were not detected.



230 Figure 4. ESBL gene prevalence in ESBL-*E. coli* carriage isolates from the Tromsø7 study 232 (n=166) and clinical isolates from NORM 2014 (n=118).

233 The clinical isolates showed an overall higher proportion of phenotypic resistance compared 234 to the carriage isolates (Table 2, Suppl. Table 3). Only 2.4% of carriage isolates were 235 phenotypically resistant to piperacillin-tazobactam compared to 31.8% (p<0.001) of clinical 236 isolates. We also detected a high prevalence of phenotypic co-resistance to non-β-lactam 237 antibiotics such as gentamicin, ciprofloxacin and trimethoprim-sulfamethoxazole both in 238 clinical and carriage isolates. Isolates co-resistant to all these three antibiotic classes, 239 accounted for 10.2% (17/166) of carriage and 33.1% (39/118, p<0.001) of clinical isolates.

240

## 241 **Table 2.** Susceptibility profile of ESBL-*E. coli* carriage isolates from Tromsø7 (n=166) and



242 clinical isolates from NORM 2014 (n=118).

243 S, susceptible; I, susceptible, increased exposure; R, Resistant; i.v. intravenous; NA, not available; \*Breakpoints  $244$  for uncomplicated urinary tract infections: tavailable for blood culture isolates only (n=85); 244 for uncomplicated urinary tract infections; †available for blood culture isolates only (n=85); ‡available for urine culture isolates only (n=33)

culture isolates only  $(n=33)$ 

246

247 Phenotypic ciprofloxacin resistance was different for ST131 (70.0%) vs. non-ST131 (26.2%, 248 p<0.001) among carriage isolates (Suppl. Table 6) in contrast to the clinical isolates (Suppl. 249 Table 7). Two carriage isolates of ST484 and ST1324 (both phylogroup A) were 250 phenotypically resistant to colistin and harbored *mcr*-1.1 and *mcr*-3.5, respectively. No 251 isolates expressed clinical resistance against carbapenems. However, two clinical isolates of 252 ST95 (phylogroup B2) and ST410 (phylogroup C) harbored *bla*<sub>IMP-26</sub> and *bla*<sub>OXA-181</sub>, 253 respectively. All isolates were susceptible to tigecycline.

254 Despite the overall higher proportion of phenotypic resistance among clinical isolates, the

255 average number of different plasmid replicon-types per isolate (both 3.1/isolate) did not differ



- 263 *ESBL-K. pneumoniae carriage isolates*
- 264 We detected only four ESBL-Kp, each of a different ST (ST29, ST211, ST261 and ST2459)
- 265 harboring  $bla_{\text{CTX-M-15}}$  (n=2),  $bla_{\text{CTX-M-14}}$  (n=1), or  $bla_{\text{SHV-12}}$  (n=1). None of the isolates were
- 266 genomically assigned as hypervirulent.

### 267 **Discussion**

268 Our study contributes to the knowledge of prevalence of, and factors associated with, ESBL-269 Ec/Kp gastrointestinal carriage in a general adult population, and the bacterial population 270 structure of carriage isolates. The comparison to a contemporary collection of clinical ESBL-271 Ec isolates revealed differences in the population structure and the prevalence of phenotypic 272 resistance between carriage and clinical isolates. Travel to Asia was identified as a major risk 273 for ESBL-Ec gastrointestinal carriage.

274 An ESBL-Ec carriage prevalence of 3.3% (2.8-3.9) is lower but comparable to previous 275 community-based data from Europe including Sweden 4.4% (3.5-5.3, n=2,134, data collected 276 2012-2013)<sup>13</sup>, the Netherlands 4.5% (3.9-5.1, n=4,177, 2014-2016)<sup>14</sup> and a Norwegian study 277 4.9% (2.7-8.1, n=284, 2014-2016)<sup>17</sup> using similar screening approaches.

278 We identified significant differences in the ESBL-Ec population structure between the 279 community and clinical isolates. The globally disseminated phylogroup B2 clone ST131 has

280 been identified as a key contributor to the increase in ESBL prevalence<sup>38</sup> and in a longitudinal 281 study of *E. coli* bloodstream isolates we identified ST131 to be the single largest contributor 282 to the increase in prevalence of ESBL-Ec in Norway.<sup>25</sup> We also observed the predominance 283 of ST131 in both our collections. However, the proportion is significantly lower in carriage 284 isolates due to lower numbers of the multidrug resistant subclade C2. Moreover, the carriage 285 population had a higher proportion of phylogroup A, associated with asymptomatic intestinal 286 carriage in humans<sup>39,40</sup> and a significantly greater ST diversity overall, compared to the 287 clinical isolates. These observations indicate that acquisition of ESBL genes frequently occur 288 in a variety of *E. coli* lineages colonizing the gut. However, there are differences in the 289 colonization potential of *E. coli* lineages and the risk of invasive infection by ESBL-Ec which 290 seems to be clone dependent.<sup>38,41</sup> The higher odds for infection that we detected for ST131 is 291 similar to that of the Swedish study (AOR 3.4, 1.8-6.4) indicating a higher pathogenicity 292 potential of ST131 compared to commensal *E. coli* lineages of phylogroup A, such as ST10.<sup>13</sup> 293 Moreover, we found that ST131 subclade A, previously reported with less resistance, and the 294 multidrug resistant subclade C2 had higher odds for infection, and this may contribute to the 295 sustained establishment of these subclades among bloodstream infections in Norway.<sup>25</sup>

296 Assuming a 100% colonization rate of *E. coli*, the large proportion of STs notorious as 297 common causes of extra-intestinal clinical infections (e.g. ST131, ST405, ST38 and 298 ST648)<sup>25,27,28</sup> could at least partly explain the higher prevalence of ESBL among *E. coli* 299 causing bloodstream infections in Norway  $(5.8\%$  in 2016)<sup>42</sup> compared to the carriage 300 prevalence of 3.3% identified here. We also observed emerging clones such as ST1193 which 301 appears to have disseminated rapidly worldwide over the last decade.<sup>35,36</sup> The low prevalence 302 of ESBL-Kp gastrointestinal carriage (0.08%) is consistent with previous community based 303 reports.  $9,14,17$ 

304 The identification of clusters with closely related isolates could indicate putative clonal 305 spread. This could include within-household and social network transmission or nosocomial 306 spread. However, we did not have access to epidemiological data to examine this further.

307 In line with other studies, we found a strong association between ESBL-Ec carriage and travel 308 to Asian regions.<sup>13-15,17,22</sup> This supports the current patient screening recommendations for 309 ESBL-producing gram-negative bacteria after hospital stay abroad in the past year before 310 hospital admission in Norway.<sup>43</sup> In contrast to a Swedish and a Dutch study,<sup>15,44</sup> we did not 311 identify travelers' diarrhea as a risk factor for ESBL-Ec carriage. However, our study was not 312 designed to specifically investigate international travelers but rather focused on risk factors in 313 the general adult population.

314 We found no association between ESBL-Ec gut carriage and factors such as hospitalization, 315 antibiotic use, and acid suppressive medication, and conflicting results have been detected in 316 previous studies.<sup>22,45</sup> Hospitalization as a risk factor has mainly been reported from studies 317 investigating patients with ESBL-E infections.<sup>23,46</sup> In line with most studies that assessed risk 318 factors regarding ESBL-E carriage in individuals in the community, we did not identify 319 hospitalization as an independent risk factor.<sup>13,22,44</sup> This may be due to the increased ESBL 320 prevalence not only in hospitals, but also in the community over the last decades and implies 321 that boundaries have become blurred between those two settings.  $9,22,47,48$ 

322 The nonsignificant effect of antibiotic use is mainly due to limitations of the drug variable in 323 our study which is based on self-reported data, including topical antibiotics and covers only 324 the last two weeks before self-sampling. As antibiotic use has been found as a risk factor for 325 resistance in many other studies,  $14,15,22$  we cannot rule out that antibiotic use plays a role in 326 ESBL-E carriage. There are reports identifying an association between the use of gastric acid 327 suppressive medication and intestinal colonization or infections with ESBL-E.<sup>18,21,23,33,34,46</sup>

328 However, a Dutch study comparable to ours did not find an association between proton pump

329 inhibitor use and ESBL-E carriage in the overall analysis.<sup>14</sup>

330 Interestingly, we found a possible association between Kp and ESBL-Ec carriage. An 331 association between ESBL-E carriage and vancomycin-resistant enterococci (VRE) has been 332 described previously<sup>7,49</sup>, and also that VRE colonization is significantly associated with Kp 333 colonization among intensive care unit patients.<sup>50</sup> These associations warrant further 334 investigations to assess if a common set of risk factors for carriage of different clinically 335 important pathogens can be identified.

336 An important strength of our study is the non-selective recruitment from the official 337 population-registry, and the high participation (87%) compared to 18.3% and 18.8% in 338 comprehensive studies from the Netherlands<sup>14</sup> and Sweden<sup>13</sup>, respectively. It is a limitation 339 that we only captured the general population 40 years and older. However, other studies have 340 not found an association between age and ESBL-E carriage.<sup>13,14</sup> Moreover, more extensive 341 data on drug use would have strengthened the analyses. Additionally, the genomic diversity of 342 carriage isolates is likely to be underestimated due to the isolation and sequencing of only one 343 colony per fecal sample. Although, we compared local carriage isolates with a national 344 collection of clinical ESBL-Ec, there was no discernible spatiotemporal spread or 345 phylogenetic structure within Norway according to a nationwide genomic study on *E. coli*  346 causing bloodstream infections. $^{25}$ 

#### 347 **Conclusions**

348 The prevalence of ESBL-Ec carriage in a general adult urban Norwegian population was low 349 reflecting the relatively low prevalence of ESBL-Ec in clinical isolates. Travel to Asia was 350 the only independent risk factor for ESBL-Ec carriage and should be considered in terms of 351 screening recommendations before hospital admission. The differences in ESBL-Ec



- 370
- 371
- 372

373

374



375

376 **Figure 5.** Flow diagram of the study population, Tromsø7, 2015-2016. \*Study population screened for *K. pneumoniae* carriage is described in.<sup>32</sup>

378 A selection of 9,320 persons attending the first visit, were invited for a second visit, also 379 including 3,154 former Tromsø Study participants not already included in the random 380 selection process, which was required for other clinical research purposes. From March 2015 381 to March 2016, 5,800 participants at the first visit were consecutively provided a fecal self-382 sampling kit. Participants collected fecal material using nylon-flocked ESwab 490CE.A

383 (Copan, Brescia, Italy). In total, 87% (n=5,042) returned a sample either at the second visit, or 384 by mail to the laboratory.

385 All 5,042 fecal samples were screened for the presence of ESBL-producing Ec and Kp via 386 selective culture (see below). All participants completed two self-administered structured 387 questionnaires on socio-demographics, smoking, alcohol use, hospitalization, drug use, and 388 travel abroad. We excluded 13 participants with wrong or missing sample identification 389 number, two retracting consent to medical research, and 28 with incomplete questionnaires 390 for a final study population of 4,999 participants (Figure 5). We analyzed the association 391 between ESBL-Ec gastrointestinal carriage and different risk factors in 4,996 participants 392 (Figure 5 and Table 1). Next, we investigated the association between ESBL-Ec carriage and 393 Kp gastrointestinal carriage among 2,972 participants additionally screened for Kp in our 394 previous study,<sup>32</sup> irrespective of resistance (Figure 5, Supplementary Table 2).

### 395 *Isolation of ESBL-producing E. coli and K. pneumoniae*

396 We added 200 µl 85% glycerol to the ESwab tubes upon arrival at the local microbiological 397 laboratory, and stored the samples at  $-80^{\circ}$ C. From the thawed media, 100 µl were plated onto 398 CHROMagar<sup>TM</sup> ESBL (CHROMagar, Paris, France) and incubated for 48 hours at 37°C. 399 Pink, purple and blue colonies suspected of being ESBL-producing Ec or *Klebsiella* spp. were 400 identified using mass spectrometry (MALDI-TOF, Bruker Daltonics, Bremen, Germany). The 401 first colony identified as either Ec, *K. pneumoniae* or *K. variicola* from each sample was kept 402 and further analyzed. All samples were plated on cysteine lactose electrolyte deficient agar 403 (MAST Group, Bootle, UK) to assess growth of fecal flora and validity of the samples.

# 404 *K. pneumoniae isolation*

405 The screening strategy and isolation procedure for Kp, is described in detail elsewhere<sup>32</sup>. 406 Briefly, we plated and screened the fecal samples onto the selective SCAI (Simons citrate

407 agar with inositol; both Sigma-Aldrich, Darmstadt, Germany) medium and identified 408 suspected colonies using MALDI-TOF.

## 409 *Antimicrobial susceptibility testing and phenotypic ESBL-identification*

410 Susceptibility testing was performed according to the EUCAST broth microdilution method 411 for carriage isolates, disc diffusion method<sup>51</sup> for the clinical isolates and both interpreted 412 using the EUCAST 2023 breakpoint table (https://eucast.org/). For the confirmation of ESBL-413 producing Ec and Kp, we followed the EUCAST algorithm for phenotypic detection of 414 ESBLs using the BD BBL<sup>TM</sup> combination disk test (Becton Dickinson and Company, Sparks, 415 USA).

# 416 *Genomic sequencing and bioinformatic analysis*

417 Genomic DNA from 166 Ec of the Tromsø7 collection was extracted with the MagNA Pure 418 96 system (Roche Applied Science, Mannheim, Germany) and sequencing libraries were 419 prepared according to the Nextera Flex sample preparation protocol (Illumina, San Diego, 420 CA, USA). Samples were sequenced on the Illumina MiSeq platform to generate 300 bp 421 paired-end reads. All reads were trimmed with TrimGalore v0.6.4 and assembled with 422 Unicycler v0.4.8 including SPAdes v3.13.0.<sup>52-54</sup> STs were assigned using the multi locus 423 sequence type (MLST) software *E.coli* scheme v2.19.0 and Enterobase.<sup>55-57</sup> AMRFinderPlus 424 v3.10.16 was used to determine resistance genes among the Ec isolates.<sup>58</sup> Plasmid replicons 425 were identified using Abricate v1.0.1 including the PlasmidFinder 2021-Mar-27 database.<sup>59,60</sup> 426 Phylogroup assignment was based on ClermonTyping v20.03 (Mar. 2020).<sup>61</sup> The *fimH* type 427 was identified using FimTyper v1.0 and BLAST+ v2.12.0.<sup>62,63</sup> Regarding the *Klebsiella* 428 isolates, Kleborate v2.0.0 was used to determine species identification, ST and acquired genes 429 encoding virulence or antibiotic resistance. $64,65$ 

430 The clinical ESBL-producing Ec included 118 isolates out of 123 representing all ESBL-Ec 431 isolates collected in  $2014^{66}$ , as part of the yearly surveillance program in NORM. Genome 432 sequencing of five isolates were unsuccessful. Before sequencing, the NORM 2014 isolates 433 were stored at -80°C and then sent to GATC Biotech AG (part of Eurofins 434 Genomics/Eurofins Scientific) in Germany for DNA isolation and WGS. Raw reads were 435 trimmed using Trimmomatic v0.39 and assembled with SPAdes v3.15.0.<sup>67,68</sup> Contigs shorter 436 than 200 bp were discarded. The genomic data were analyzed as described above.

#### 437 *Phylogenetic and population structure analysis of ESBL-E. coli*

438 We used Prokka v.1.14.6<sup>69</sup> to annotate genomes and snippy v.4.6.0<sup>70</sup> to map the sequence 439 reads to the ST131 Ec EC958 chromosome [HG941718.1] 440 (https://www.ncbi.nlm.nih.gov/nuccore/HG941718.1) to create the core genome alignment. 441 We used snp-dists v.0.8.2, (https://github.com/tseemann/snp-dists/) to create the SNP distance 442 matrix from the core genome alignment. We used a 17 SNP cut-off to define similarity 443 between two genomes and to identify probable ESBL-Ec transmission events among cases.<sup>37</sup> 444 To assess the phylogenetic relatedness, we used the core SNP alignment to infer a maximum-445 likelihood tree using RAxML v.8.2.8 with the GTR + Gamma rate model and 100 rapid 446 bootstraps visualized in iTol  $(v6.5.2)$ .<sup>71,72</sup> ST131 subclades were determined based on 447 subclade specific SNPs and *fimH* alleles, subclade membership was corrected when 448 assignment based on SNP profile of sporadic isolates did not fit with the phylogenetic 449 distribution of clades.  $25,30,62,73$ 

450 *Statistical analysis* 

451 Our primary analyses were multivariable logistic regression models, performed in two 452 overlapping study populations with outcome variable ESBL-Ec gastrointestinal carriage using 453 SPSS v.26.0 (SPSS, Inc., Chicago, IL, USA). First, we analyzed factors associated with

454 ESBL-Ec gastrointestinal carriage among 4,996 participants (Table 1). Next, in 2,972 455 participants also screened for  $Kp<sub>1</sub><sup>32</sup>$  we performed a multivariable logistic regression analysis 456 including Kp carriage as an additional explanatory variable (Suppl. Table 2). Explanatory 457 variables were selected with the help of a directed acyclic graph constructed using DAGitty 458 v3.0 (Suppl. Figure 3 and 4).<sup>74</sup> All explanatory variables were kept in the fully adjusted 459 models. Multicollinearity between the entered variables was assessed calculating the variance 460 inflation factor (VIF) and tolerance statistic. Multicollinearity was not a problem with VIF>10 461 and tolerance statistic  $\langle 0.2 \rangle^{75}$  The strength of the associations was examined by calculating 462 AORs with 95% CI. Two-sided p-values <0.05 were considered statistically significant. The 463 prevalence of ST131 among carrier and clinical isolates was compared calculating the OR 464 with 95% CI using logistic regression in SPSS. The comparison of proportions was assessed 465 using  $\chi^2$ -test.

# 466 **Ethics**

467 The study was approved by the Regional Committee for Medical and Health Research Ethics, 468 North Norway (REC North reference: 2016/1788 and 2014/940) and the Data Protection 469 Officer at University Hospital of North Norway (reference: 2019/4264). The study complied 470 with the Declaration of Helsinki. All participants in Tromsø7 signed an informed consent 471 form prior to participation.

## 472 **Acknowledgements**

473 We are grateful for technical assistance from Bjørg Haldorsen, Bettina Aasnæs and Ellen 474 Josefsen in organizing the collection of fecal samples in the laboratory, Eva Bernhoff and 475 Ragna-Johanne Bakksjø for performing WGS, Marit Andrea Klokkhammer Hetland for initial 476 sequence analysis of carriage isolates. Rod Wolstenholme for figure editing. We thank

477 Sigma2, the national provider of e-infrastructure, for access to High-Performance Computing 478 and large-scale data storage (Project ID: NN9794K).

479 Collaborators forming the Norwegian *E. coli* ESBL Study Group include: Nina Handal 480 (Akershus University Hospital), Elisabeth Sirnes (Førde Hospital), Liv Jorunn Hafne 481 (Haugesund Hospital), Paul Christoffer Lindemann (Haukeland University Hospital), Lovise 482 Marie Norgaard (Innlandet Hospital), Kyriakos Zaragkoulias (Levanger Hospital), Einar 483 Nilsen (Molde and Ålesund Hospital), Hege Elisabeth Larsen (Nordland Hospital), Marcela 484 Pino (Oslo University Hospital, Rikshospitalet), Nils Olav Hermansen (Oslo University 485 Hospital, Ullevål), Iren H. Löhr (Stavanger University Hospital), Aleksandra Jakovljev (St. 486 Olav University Hospital), Ståle Tofteland (Sørlandet Hospital), Kristina Papp (Unilabs 487 Telelab), Gunnar Skov Simonsen (University Hospital of North Norway), Åshild Marvik 488 (Vestfold Hospital), Nadine Durema Pullar (Vestre Viken, Bærum Hospital), Roar Magne 489 Bævre-Jensen (Vestre Viken, Drammen Hospital), Anita Kanestrøm (Østfold Hospital).

### 490 **Author contributions:**

491 ØS conceptualized and acquired funding for the study in collaboration with AS, KG and IHL. 492 ØS was responsible for organizing the collection of fecal samples. LLEA did the screening of 493 fecal samples and phenotypic testing. NR, KS, LS and KG conceptualized and conducted the 494 epidemiological analysis of risk factors. IHL organized WGS of carriage isolates. GSS and 495 the Norwegian *E. coli* ESBL Study Group provided data and clinical isolates. DJB, AKP, NR 496 and ØS analyzed the WGS data. NR, ØS, KS and KG prepared first manuscript draft. All 497 authors contributed to review and editing of the manuscript and approved the final version.

# 498 **Declaration of interests:**

499 All authors report no conflicts of interest.

500 **Role of funding source**

501 This study was supported by grants from the Northern Norway Regional Health Authority 502 (HNF1415-18) and the Trond Mohn Foundation (TMF2019TMT03). The funders of the study 503 played no role in study design, data collection, data analysis, data interpretation, or writing of 504 the report.

#### 505 **Data Availability**

506 Bacterial genome data (raw Illumina reads) are publicly available in NCBI under BioProject 507 PRJEB53319 (NORM 2014 collection) and PRJEB57251 (Tromsø7 collection). This study is 508 based on data owned by a third party (The Tromsø Study, Department of Community 509 Medicine, UiT The Arctic University of Norway). Confidentiality requirements according to 510 Norwegian law prevents sharing of individual patient level data in public repositories. 511 Application of legal basis and exemption from professional secrecy requirements for the use 512 of personal health data in research may be sent to a regional committee for medical and health 513 research ethics (https://rekportalen.no/). The authors gained access to the data through the 514 Tromsø Study's application process. Guidelines on how to access the data are available at the 515 website https://uit.no/research/tromsostudy. All enquiries about the Tromsø Study should be 516 sent by e-mail to  $t$ romsous@ism.uit.no. All the questionnaire variables are published in the 517 NESSTAR program system and results can be viewed online: 518 http://tromsoundersokelsen.uit.no/tromso/.

# 519 **References**

- 520 1. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a 521 systematic analysis. *Lancet.* 2022 Feb 12;399(10325):629-655.
- 522 2. NORM/NORM-VET 2021. Usage of antimicrobial agents and occurrence of antimicrobial 523 resistance in Norway. Tromsø/Oslo/Ås; 2022. ISSN: 1502-2307 (print)/1890- 9965 524 (electronic).
- 525 3. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with 526 extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a
- 527 systematic review and meta-analysis. *J Antimicrob Chemother.* 2007 Nov;60(5):913-20.

528 4. Scheuerman O, Schechner V, Carmeli Y, et al. Comparison of predictors and mortality 529 between bloodstream infections caused by ESBL-producing *Escherichia coli* and ESBL-

530 producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol.* 2018 Jun;39(6):660-667.

531 5. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new

532 antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet*  533 *Infect Dis.* 2018 Mar;18(3):318-327.

534 6. Prevel R, Boyer A, M'Zali F, et al. Extended spectrum beta-lactamase producing 535 Enterobacterales faecal carriage in a medical intensive care unit: low rates of cross-

536 transmission and infection. *Antimicrob Resist Infect Control*. 2019 Jul 10;8:112.<br>537 7. Wyres KL, Hawkey J, Mirceta M, et al. Genomic surveillance of antimicr 537 7. Wyres KL, Hawkey J, Mirceta M, et al. Genomic surveillance of antimicrobial resistant 538 bacterial colonisation and infection in intensive care patients. *BMC Infect Dis.* 2021 Jul 539 14;21(1):683.

- 540 8. Denkel LA, Maechler F, Schwab F, et al. Infections caused by extended-spectrum beta-541 lactamase-producing Enterobacterales after rectal colonization with ESBL-producing 542 *Escherichia coli* or *Klebsiella pneumoniae*. *Clin Microbiol Infect.* 2020 Aug;26(8):1046-
- 543 1051.

544 9. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of 545 extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. 546 *Clin Microbiol Rev.* 2013 Oct;26(4):744-58.

547 10. Bezabih YM, Sabiiti W, Alamneh E, et al. The global prevalence and trend of human 548 intestinal carriage of ESBL-producing *Escherichia coli* in the community. *J Antimicrob*  549 *Chemother.* 2021 Jan 1;76(1):22-29.

550 11. Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in 551 U.S. Hospitalized Patients, 2012-2017. *N Engl J Med.* 2020 Apr 2;382(14):1309-1319.

552 12. Mughini-Gras L, Dorado-Garcia A, van Duijkeren E, et al. Attributable sources of 553 community-acquired carriage of *Escherichia coli* containing beta-lactam antibiotic resistance

554 genes: a population-based modelling study. *Lancet Planet Health.* 2019 Aug;3(8):e357-e369*.*

555 13. Ny S, Lofmark S, Borjesson S, et al. Community carriage of ESBL-producing 556 *Escherichia coli* is associated with strains of low pathogenicity: a Swedish nationwide study. 557 *J Antimicrob Chemother.* 2017 Feb;72(2):582-588.

558 14. van den Bunt G, van Pelt W, Hidalgo L, et al. Prevalence, risk factors and genetic 559 characterisation of extended-spectrum beta-lactamase and carbapenemase-producing 560 Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the 561 Netherlands, 2014 to 2016. *Euro Surveill.* 2019 Oct;24(41):1800594.

562 15. Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-563 spectrum beta-lactamase-producing Enterobacteriaceae by international travellers (COMBAT

564 study): a prospective, multicentre cohort study. *Lancet Infect Dis.* 2017 Jan;17(1):78-85.

565 16. Jorgensen SB, Samuelsen O, Sundsfjord A, et al. High prevalence of faecal carriage of

566 ESBL-producing Enterobacteriaceae in Norwegian patients with gastroenteritis. *Scand J*  567 *Infect Dis.* 2014 Jun;46(6):462-5.

568 17. Ulstad CR, Solheim M, Berg S, Lindbaek M, Dahle UR, Wester AL. Carriage of

569 ESBL/AmpC-producing or ciprofloxacin non-susceptible *Escherichia coli* and *Klebsiella* spp.

570 in healthy people in Norway. *Antimicrob Resist Infect Control.* 2016 Dec 15;5:57.

571 18. Kohler P, Seiffert SN, Kessler S, et al. Molecular Epidemiology and Risk Factors for 572 Extended-Spectrum beta-Lactamase-Producing Enterobacterales in Long-Term Care

573 Residents. *J Am Med Dir Assoc.* 2022 Mar;23(3):475-481.e5.

574 19. Rettedal S, Lohr IH, Bernhoff E, Natas OB, Sundsfjord A, Oymar K. Extended-spectrum

575 beta-lactamase-producing Enterobacteriaceae among pregnant women in Norway: prevalence

576 and maternal-neonatal transmission. *J Perinatol.* 2015 Nov;35(11):907-12.

- 577 20. Birgy A, Cohen R, Levy C, et al. Community faecal carriage of extended-spectrum beta-578 lactamase-producing Enterobacteriaceae in French children. *BMC Infect Dis.* 2012 Nov
- 579 21;12:315.
- 580 21. Wielders CCH, van Hoek A, Hengeveld PD, et al. Extended-spectrum β-lactamase- and
- 581 pAmpC-producing Enterobacteriaceae among the general population in a livestock-dense 582 area. *Clin Microbiol Infect.* 2017 Feb;23(2):120.e1-120.e8.
- 583 22. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with 584 extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among 585 healthy individuals: A systematic review and metaanalysis. *Clin Infect Dis.* 2016 Aug 586 1;63(3):310-8.
- 587 23. Richelsen R, Smit J, Laxsen Anru P, Schønheyder HC, Nielsen H. Risk factors of 588 community-onset extended-spectrum β-lactamase *Escherichia coli* and *Klebsiella*  589 *pneumoniae* bacteraemia: an 11-year population-based case-control-control study in 590 Denmark. *Clin Microbiol Infect.* 2021 Jun;27(6):871-877.
- 591 24. Leistner R, Meyer E, Gastmeier P, et al. Risk factors associated with the community-592 acquired colonization of extended-spectrum beta-lactamase (ESBL) positive *Escherichia coli*.
- 593 an exploratory case-control study. *PLoS One.* 2013 Sep 11;8(9):e74323.
- 594 25. Gladstone RA, McNally A, Pontinen AK, et al. Emergence and dissemination of 595 antimicrobial resistance in *Escherichia coli* causing bloodstream infections in Norway in
- 596 2002-17: a nationwide, longitudinal, microbial population genomic study. *Lancet Microbe.*  597 2021 Jul;2(7):e331-e341.
- 598 26. Fostervold A, Hetland MAK, Bakksjø R, et al. A nationwide genomic study of clinical
- 599 *Klebsiella pneumoniae* in Norway 2001-2015: Introduction and spread of ESBL facilitated by
- 600 CG15 and CG307. *J Antimicrob Chemother.* 2022 Feb 23;77(3):665-674.
- 601 27. Dunn SJ, Connor C, McNally A. The evolution and transmission of multi-drug resistant
- 602 *Escherichia coli* and *Klebsiella pneumoniae*: the complexity of clones and plasmids. *Curr*  603 *Opin Microbiol.* 2019 Oct;51:51-56.
- 604 28. Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global extraintestinal 605 pathogenic *Escherichia coli* (ExPEC) lineages. *Clin Microbiol Rev.* 2019 Jun 606 12;32(3):e00135-18.
- 607 29. Kallonen T, Brodrick HJ, Harris SR, et al. Systematic longitudinal survey of invasive 608 *Escherichia coli* in England demonstrates a stable population structure only transiently 609 disturbed by the emergence of ST131. *Genome Res.* 2017 Jul 18;27(8):1437-1449.
- 610 30. Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, et al. Sequential acquisition of
- 611 virulence and fluoroquinolone resistance has shaped the evolution of *Escherichia coli* ST131. 612 *mBio.* 2016 Apr 26;7(2):e00347-16.
- 613 31. Hopstock LA, Grimsgaard S, Johansen H, Kanstad K, Wilsgaard T, Eggen AE. The 614 seventh survey of the Tromsø Study (Tromsø7) 2015-2016: study design, data collection, 615 attendance, and prevalence of risk factors and disease in a multipurpose population-based
- 616 health survey. *Scand J Public Health.* 2022 Nov;50(7):919-929.
- 617 32. Raffelsberger N, Hetland MAK, Svendsen K, et al. Gastrointestinal carriage of *Klebsiella*
- 618 *pneumoniae* in a general adult population: a cross-sectional study of risk factors and bacterial 619 genomic diversity. *Gut Microbes.* 2021 Jan-Dec;13(1):1939599.
- 620 33. Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke-Grauls C. Evaluation of the 621 association between gastric acid suppression and risk of intestinal colonization with
- 622 multidrug-resistant microorganisms: A systematic review and meta-analysis. *JAMA Intern*  623 *Med.* 2020 Apr 1;180(4):561-571.
- 624 34. Reuland EA, Al Naiemi N, Kaiser AM, et al. Prevalence and risk factors for carriage of
- 625 ESBL-producing Enterobacteriaceae in Amsterdam. *J Antimicrob Chemother.* 2016
- 626 Apr;71(4):1076-82.

- 627 35. Johnson JR, Johnston BD, Porter SB, et al. Rapid emergence, subsidence, and molecular
- 628 detection of *Escherichia coli* sequence type 1193-fimH64, a new disseminated multidrug-
- 629 resistant commensal and extraintestinal pathogen. *J Clin Microbiol.* 2019 Apr 630 26;57(5):e01664-18.
- 631 36. Tchesnokova V, Radey M, Chattopadhyay S, et al. Pandemic fluoroquinolone resistant
- 632 *Escherichia coli* clone ST1193 emerged via simultaneous homologous recombinations in 11 633 gene loci. *Proc Natl Acad Sci U S A.* 2019 Jul 16;116(29):14740-14748.
- 634 37. Ludden C, Coll F, Gouliouris T, et al. Defining nosocomial transmission of *Escherichia*
- 635 *coli* and antimicrobial resistance genes: a genomic surveillance study. *Lancet Microbe.* 2021
- 636 Sep;2(9):e472-e480.
- 637 38. Nicolas-Chanoine MH, Bertrand X, Madec JY. *Escherichia coli* ST131, an intriguing 638 clonal group. *Clin Microbiol Rev.* 2014 Jul;27(3):543-74.
- 639 39. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal 640 *Escherichia coli*. *Nat Rev Microbiol.* 2010 Mar;8(3):207-17.
- 641 40. Denamur E, Clermont O, Bonacorsi S, Gordon D. The population genetics of pathogenic 642 *Escherichia coli*. *Nat Rev Microbiol.* 2021 Jan;19(1):37-54.
- 643 41. Marin J, Clermont O, Royer G, et al. The population genomics of increased virulence and
- 644 antibiotic resistance in human commensal *Escherichia coli* over 30 years in France. *Appl*  645 *Environ Microbiol.* 2022 Aug 9;88(15):e0066422.
- 646 42. NORM/NORM-VET 2016. Usage of antimicrobial agents and occurrence of antimicrobial
- 647 resistance in Norway. Tromsø/Oslo; 2017. ISSN: 1502-2307 (print)/1890- 9965 (electronic).
- 648 43.Health NIoP. ESBL-holdige gramnegative stavbakterier smitteverntiltak i 649 helseinstitusjoner. 2015. https://www.fhi.no/sv/forebygging-i-helsetjenesten/smittevern-i-650 institusjoner/tiltak/esbl-holdige-gramnegative-stavbakte/.
- 651 44. Ostholm-Balkhed A, Tarnberg M, Nilsson M, et al. Travel-associated faecal colonization 652 with ESBL-producing Enterobacteriaceae: incidence and risk factors. *J Antimicrob*  653 *Chemother*
- 654 *.* 2013 Sep;68(9):2144-53.
- 655 45. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, et al. 10-Fold increase (2006-11) in
- 656 the rate of healthy subjects with extended-spectrum β-lactamase-producing *Escherichia coli* 657 faecal carriage in a Parisian check-up centre. *J Antimicrob Chemother.* 2013 Mar;68(3):562-8.
- 658 46. Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schønheyder HC, Vandenbroucke-
- 
- 659 Grauls C. Risk factors for extended-spectrum β-lactamase-producing *Escherichia coli* urinary 660 tract infection in the community in Denmark: a case-control study. *Clin Microbiol Infect.*  661 2017 Dec;23(12):952-960.
- 662 47. Vihta K-D, Stoesser N, Llewelyn MJ, et al. Trends over time in *Escherichia coli*
- 663 bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, 664 UK, 1998–2016: a study of electronic health records. *Lancet Infect Dis.* 2018 665 Oct;18(10):1138-1149.
- 666 48. Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-667 spectrum β-lactamase-producing *Escherichia coli* in community hospitals throughout the 668 Southeastern United States. *Infect Control Hosp Epidemiol.* 2016 Jan;37(1):49-54.
- 
- 669 49. Reddy P, Malczynski M, Obias A, et al. Screening for extended-spectrum β-lactamase-670 producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. 671 *Clin Infect Dis.* 2007 Oct 1;45(7):846-52.
- 672 50. Collingwood A, Blostein F, Seekatz AM, et al. Epidemiological and microbiome
- 673 associations between *Klebsiella pneumoniae* and vancomycin-resistant *Enterococcus*
- 674 colonization in intensive care unit patients. *Open Forum Infect Dis.* 2020 Jan 12;7(1):ofaa012.

- 675 51. Matuschek E, Brown DF, Kahlmeter G. Development of the EUCAST disk diffusion 676 antimicrobial susceptibility testing method and its implementation in routine microbiology 677 laboratories. *Clin Microbiol Infect.* 2014 Apr;20(4):O255-66.
- 678 52. Krueger F. TrimGalore. 2019. https://github.com/FelixKrueger/TrimGalore (accessed 679 August 2019.
- 680 53. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome 681 assemblies from short and long sequencing reads. *PLoS Comput Biol.* 2017 Jun 682 8;13(6):e1005595.
- 683 54. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and 684 its applications to single-cell sequencing. *J Comput Biol.* 2012 May;19(5):455-77.
- 685 55. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb 686 software, the PubMLST.org website and their applications. *Wellcome Open Res.* 2018 Sep 687 24;3:124.
- 688 56. Seemann T. mlst Github. 2021. https://github.com/tseemann/mlst2021).
- 689 57. Zhou Z, Alikhan NF, Mohamed K, Fan Y, Achtman M. The EnteroBase user's guide, with 690 case studies on *Salmonella* transmissions, *Yersinia pestis* phylogeny, and *Escherichia* core
- 691 genomic diversity. *Genome Res.* 2020 Jan;30(1):138-152.
- 692 58. Feldgarden M, Brover V, Gonzalez-Escalona N, et al. AMRFinderPlus and the reference 693 gene catalog facilitate examination of the genomic links among antimicrobial resistance, 694 stress response, and virulence. *Sci Rep.* 2021 Jun 16;11(1):12728.
- 695 59. Carattoli A, Zankari E, Garcia-Fernandez A, et al. In silico detection and typing of 696 plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents*  697 *Chemother.* 2014 Jul;58(7):3895-903.
- 698 60. Seemann T. *Abricate*, Github. 2019. https://github.com/tseemann/abricate.
- 699 61. Beghain J, Bridier-Nahmias A, Le Nagard H, Denamur E, Clermont O. ClermonTyping:
- 700 an easy-to-use and accurate in silico method for *Escherichia* genus strain phylotyping. *Microb*  701 *Genom.* 2018 Jul;4(7):e000192.
- 702 62. Roer L, Tchesnokova V, Allesøe R, et al. Development of a web tool for *Escherichia coli* 703 subtyping based on *fim*H alleles. *J Clin Microbiol.* 2017 Aug;55(8):2538-2543.
- 704 63. Madden T. The BLAST sequence analysis tool. in: McEntyre J OJ, editor. 705 http://www.ncbi.nlm.nih.gov/books/NBK21097/: The NCBI Handbook. Bethesda (MD): 706 National Center for Biotechnology Information (US); 2002-. Chapter 16.; 2002.
- 707 64. Lam MM, Wick RR, Wyres KL, Holt KE. A genomic surveillance framework and 708 genotyping tool for *Klebsiella pneumoniae* and its related species complex *Nat Commun.* 709 2021 Jul 7;12(1):4188.
- 710 65. Lam MMC, Wyres KL, Judd LM, et al. Tracking key virulence loci encoding aerobactin
- 711 and salmochelin siderophore synthesis in *Klebsiella pneumoniae*. *Genome Med.* 2018 Oct 712 29;10(1):77.
- 713 66. NORM/NORM-VET 2014. Usage of antimicrobial agents and occurrence of antimicrobial 714 resistance in Norway. Tromsø/Oslo; 2015. ISSN: 1502-2307 (print)/1890- 9965 (electronic).
- 715 67. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
- 716 data. *Bioinformatics.* 2014 Aug 1;30(15):2114-20.
- 717 68. Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes *de*  718 *novo* assembler. *Curr Protoc Bioinformatics.* 2020 Jun;70(1):e102.
- 719 69. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.* 2014 Jul 720 15;30(14):2068-9.
- 721 70. Seemann T. snippy: fast bacterial variant calling from NGS reads. 2015. 722 https://github.com/tseemann/snippy.
- 723 71. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of
- 724 large phylogenies. *Bioinformatics* 2014 May 1;**30**(9):1312-3.

- 725 72. Letunic I, Bork P. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree
- 726 display and annotation. *Nucleic Acids Res.* 2021 Jul 2;49(W1):W293-W296.
- 727 73. Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-spectrum-beta-lactamase-
- 728 producing *Escherichia coli* ST131 is driven by a single highly pathogenic subclone, *H30*-Rx.
- 729 *mBio.* 2013 Dec 17;4(6):e00377-13.
- 730 74. Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal
- 731 inference using directed acyclic graphs: the R package 'dagitty'. *Int J Epidemiol.* 2016 Dec
- 732 1;45(6):1887-1894.
- 733 75. Field A. Discovering statistics using IBM SPSS statistics: SAGE Publications Ltd; 2017.
- 734